Yael Bar

6 Weizmann St, 6423906
Tel Aviv, TA 64239, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations.

Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations.

Journal: Breast cancer research and treatment
Published: January 12, 2026

Neoadjuvant twelve weekly paclitaxel-carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer.

Neoadjuvant twelve weekly paclitaxel-carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer.

Journal: Breast cancer research and treatment
Published: December 30, 2025

Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer.

Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer.

Journal: JNCI cancer spectrum
Published: July 30, 2025

Selection biases in the systematic collection of breast biobank specimens.

Selection biases in the systematic collection of breast biobank specimens.

Journal: NPJ breast cancer
Published: January 04, 2025

Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response.

Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response.

Journal: NPJ breast cancer
Published: December 17, 2024

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies.

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies.

Journal: NPJ breast cancer
Published: December 07, 2024

The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer.

The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer.

Journal: Breast (Edinburgh, Scotland)
Published: March 11, 2024

NOVEL TECHNOLOGIES AND FUTURE TRENDS IN TRANSLATIONAL RESEARCH IN ONCOLOGY

NOVEL TECHNOLOGIES AND FUTURE TRENDS IN TRANSLATIONAL RESEARCH IN ONCOLOGY

Journal: Harefuah
Published: March 03, 2024

Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer.

Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer.

Journal: NPJ breast cancer
Published: August 29, 2023

Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA).

Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA).

Journal: Breast cancer research and treatment
Published: August 14, 2023

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer.

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer.

Journal: Therapeutic advances in medical oncology
Published: September 08, 2022

The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.

The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 02, 2022
Showing 1-12 of 18

Last Updated: 09/26/2026